Artelo Biosciences gets USPTO notice of allowance for ART27.13 formulation patent application

Reuters2026/08/17 12:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Artelo Biosciences received a USPTO Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13.
Claims cover ART27.13 compositions dispersed in polyethylene glycol; patent protection expected to run through 2041.
ART27.13 is being tested in two Phase 2 studies, including CAReS for cancer-related anorexia and DREAM for glaucoma or ocular hypertension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170852PRIMZONEFULLFEED9810970) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Artelo Biosciences gets USPTO notice of allowance for ART27.13 formulation patent application

You may also like

Crypto prices